Hypera S.A. - ADR
HYPMY
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.8B
Close$
$10.40
92.5% upside
Current Fair Value
92.5% upsideUndervalued by 92.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.80 Billion |
|---|---|
| Enterprise Value | $9.86 Billion |
| Dividend Yield | $0.26 (4.02%) |
| Earnings per Share | $1.89 |
| Beta | 0.11 |
| Outstanding Shares | 703,992,255 |
Return
| Return on Equity | 12.06% |
|---|---|
| Return on Assets | 6.86% |
| Return on Invested Capital | 11.79% |
Valuation & Multiples
| P/E Ratio | 10.05 |
|---|---|
| PEG | 67.47 |
| Price to Sales | 0.45 |
| Price to Book Ratio | 0.27 |
| Enterprise Value to Revenue | 1.12 |
| Enterprise Value to EBIT | 3.78 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.77 |
| Debt to Equity | 0.53 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.13
Average shareholder expectationRevenue Estimate
$452.49 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$0.14
Average shareholder expectationRevenue Estimate
$450.75 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hypera S.A.
10,564 employees
CEO: Breno Toledo Pires de Oliveira Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Ci...